Ariad Pharma (ARIA) Commences Common Stock Offering
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Join SI Premium – FREE
Ariad Pharmaceuticals, Inc. (Nasdaq: ARIA) has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by ARIAD.
J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. are acting as joint book-running managers and underwriters for the proposed offering. ARIAD intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the amount sold to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. are acting as joint book-running managers and underwriters for the proposed offering. ARIAD intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the amount sold to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exchange Traded Concepts and ARIAM Global launch ARIA an Actively Managed ETF Led by a Portfolio Manager with a Ph.D. in AI and Computer Science
- MapLight Therapeutics raises $150M in private placement
- Delek Logistics closes $230M unit offering at $50 per unit
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
JPMorgan, Jefferies & Co, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
